Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia

Autor: Joost C. M. Meijers, Danka J. F. Stuijver, Bregje van Zaane, Dees P. M. Brandjes, Chantal J. N. Verkleij, Alessandro Squizzato, Victor E. A. Gerdes, Harry R. Büller
Přispěvatelé: Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, Experimental Vascular Medicine
Rok vydání: 2013
Předmět:
Adult
Male
0301 basic medicine
Carboxypeptidase B2
endocrine system
medicine.medical_specialty
endocrine system diseases
020205 medical informatics
medicine.medical_treatment
Levothyroxine
Thyrotropin
Hemorrhage
02 engineering and technology
03 medical and health sciences
Hyperthyroxinemia
Hypothyroidism
Internal medicine
Fibrinolysis
0202 electrical engineering
electronic engineering
information engineering
medicine
Humans
Endocrine system
Single-Blind Method
Blood Coagulation
Aged
Netherlands
Aged
80 and over
Hemostasis
Cross-Over Studies
business.industry
Thyroid
Thrombosis
Hematology
Middle Aged
medicine.disease
Hyperfibrinolysis
Thyroxine
Endocrinology
medicine.anatomical_structure
Coagulation
Triiodothyronine
Female
030101 anatomy & morphology
Fibrin Clot Lysis Time
business
medicine.drug
Zdroj: Thrombosis and haemostasis, 109(2), 214-220. Schattauer GmbH
ISSN: 2567-689X
0340-6245
DOI: 10.1160/th12-07-0525
Popis: SummaryEndocrine disorders affect both the coagulation and fibrinolytic systems, and have been associated with the development of cardiovascular diseases. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a link between coagulation and the fibrinolytic system. The aim of this study was to determine the effect of thyroid hormone excess and deficiency on TAFI levels and function. The effect of hyperthyroxinemia on TAFI was studied in healthy volunteers who were randomised to receive levothyroxine or no medication for 14 days in a crossover design. The effect of hypothyroidism on TAFI was studied in a multicentre observational cohort study. Blood was drawn before treatment of patients with newly diagnosed hypothyroidism and when euthyroidism was achieved. Plasma clot-lysis times, activated TAFI (TAFIa)-dependent prolongation of clot-lysis and TAFI levels were measured. Thyroid hormone excess resulted in a hypofibrinolytic condition and in an enhanced TAFIa-dependent prolongation of clot lysis. A trend towards decreased plasma TAFI levels was observed in healthy volunteers who used levothyroxine. Hypothyroidism resulted in hyperfibrinolysis and a reduced TAFIa-dependent prolongation of clot lysis. In conclusion, alterations of TAFIa-dependent prolongation of clot lysis in patients with thyroid disorders may cause an impaired haemostatic balance. The disturbed haemostatic balance in patients with hyperthyroidism might make them prone to thrombosis, while the risk for bleeding may increase in patients with hypothyroidism.
Databáze: OpenAIRE
Externí odkaz: